Upadacitinib is an oral JAK-1 (JAK1) inhibitor that has been approved for the treatment of multiple immune-mediated inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. The gene discussed is JAK1; the disease is atopic eczema.